Global Cord Blood Co. (NYSE:CO) Short Interest Up 22.8% in April

Global Cord Blood Co. (NYSE:COGet Rating) was the recipient of a significant increase in short interest during the month of April. As of April 15th, there was short interest totalling 48,000 shares, an increase of 22.8% from the March 31st total of 39,100 shares. Approximately 0.2% of the shares of the company are sold short. Based on an average daily trading volume, of 153,000 shares, the days-to-cover ratio is presently 0.3 days.

Several institutional investors have recently bought and sold shares of CO. National Asset Management Inc. acquired a new stake in Global Cord Blood during the first quarter worth approximately $39,000. Two Sigma Advisers LP acquired a new stake in Global Cord Blood during the third quarter worth approximately $58,000. American Century Companies Inc. grew its position in Global Cord Blood by 26.2% during the third quarter. American Century Companies Inc. now owns 20,591 shares of the medical research company’s stock worth $96,000 after buying an additional 4,269 shares in the last quarter. Millennium Management LLC acquired a new stake in Global Cord Blood during the second quarter worth approximately $152,000. Finally, Citadel Advisors LLC grew its position in Global Cord Blood by 10.9% during the fourth quarter. Citadel Advisors LLC now owns 29,704 shares of the medical research company’s stock worth $124,000 after buying an additional 2,914 shares in the last quarter. 15.13% of the stock is currently owned by institutional investors.

Separately, StockNews.com assumed coverage on Global Cord Blood in a research report on Thursday, April 14th. They issued a “strong-buy” rating on the stock.

Shares of Global Cord Blood stock traded down $0.05 on Tuesday, hitting $2.40. The stock had a trading volume of 23,612 shares, compared to its average volume of 47,338. Global Cord Blood has a twelve month low of $2.10 and a twelve month high of $6.31. The company has a 50 day moving average price of $3.90. The firm has a market capitalization of $291.72 million, a PE ratio of 3.32 and a beta of 0.39.

Global Cord Blood (NYSE:COGet Rating) last posted its earnings results on Monday, February 28th. The medical research company reported $0.17 EPS for the quarter. Global Cord Blood had a return on equity of 11.42% and a net margin of 41.98%. The company had revenue of $49.78 million for the quarter.

Global Cord Blood Company Profile (Get Rating)

Global Cord Blood Corporation, together with its subsidiaries, provides umbilical cord blood storage and ancillary services in the People's Republic of China. The company offers cord blood testing, processing, and storage services under the direction of subscribers; and tests, processes, and stores donated cord blood, as well as provides matching services.

See Also

Receive News & Ratings for Global Cord Blood Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Global Cord Blood and related companies with MarketBeat.com's FREE daily email newsletter.